Tempest Therapeutics, Inc. Common Stock (TPST)
PHARMACEUTICAL PREPARATIONS
Tempest Therapeutics, Inc. Common Stock (TPST) is listed on Nasdaq, where it has traded since June 28, 2021.
- Listed On
- Nasdaq
- Listed Since
- June 28, 2021
- Employees
- 4
- Market Cap
- $14M
About Tempest Therapeutics, Inc. Common Stock
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 20 institutions reported holding TPST, with 1.3 million shares worth $1.4 million in aggregate. The largest reported holder was Sabby Management, with 511,286 shares worth $567,527. Of the 5 largest holders listed below, 1 added shares, 1 reduced its position and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Sabby Management | 511,286 | $568K | Added 2763.38% |
| Vanguard | 302,796 | $336K | Unchanged |
| Versant Venture Management | 269,772 | $299K | Unchanged |
| Geode Capital Management | 86,625 | $96K | Reduced 0.42% |
| BlackRock | 39,068 | $43K | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is TPST?
Tempest Therapeutics, Inc. Common Stock (TPST) is listed on Nasdaq, where it has traded since June 28, 2021.
Who are the largest institutional holders of TPST?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of TPST were Sabby Management, Vanguard and Versant Venture Management.
How many institutions own TPST?
20 institutions reported a position in TPST for the quarter ended June 30, 2026, worth $1.4 million in total.
Did institutions buy or sell TPST last quarter?
Of the 5 largest reported holders, 1 added shares, 1 reduced its position and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for TPST.
Every reported institutional holder, plus insider and congressional trades in TPST, on SentiSense.